Clozapine in drug induced psychosis in Parkinson’s disease: a randomised, placebo controlled study with open follow up
Identifieur interne : 002F29 ( Main/Exploration ); précédent : 002F28; suivant : 002F30Clozapine in drug induced psychosis in Parkinson’s disease: a randomised, placebo controlled study with open follow up
Auteurs : P. Pollak [France] ; F. Tison [France] ; O. Rascol [France] ; A. Destée [France] ; J J Péré [France] ; J M Senard [France] ; F. Durif [France] ; I. Bourdeix [France]Source :
- Journal of Neurology, Neurosurgery & Psychiatry [ 0022-3050 ] ; 2004-05.
Descripteurs français
- Pascal (Inist)
English descriptors
- KwdEn :
- Aged, CGI, clinical global impression scale, Clozapine, Clozapine (administration & dosage), Clozapine (therapeutic use), Dose-Response Relationship, Drug, Double-Blind Method, Feasibility Studies, Female, Follow up study, Follow-Up Studies, GABA Antagonists (administration & dosage), GABA Antagonists (adverse effects), Humans, Levodopa (adverse effects), MMSE, mini mental test examination, Male, Nervous system diseases, PANSS, positive and negative syndrome scale, PD, Parkinson’s disease, Parkinson Disease (drug therapy), Parkinson disease, Parkinson’s disease, Prospective Studies, Psychoses, Substance-Induced (diagnosis), Psychoses, Substance-Induced (etiology), Psychosis, UPDRS, unified Parkinson’s disease rating scale, clozapine, psychosis.
- MESH :
- chemical , administration & dosage : Clozapine, GABA Antagonists.
- chemical , adverse effects : GABA Antagonists, Levodopa.
- chemical , therapeutic use : Clozapine.
- diagnosis : Psychoses, Substance-Induced.
- drug therapy : Parkinson Disease.
- etiology : Psychoses, Substance-Induced.
- Aged, Dose-Response Relationship, Drug, Double-Blind Method, Feasibility Studies, Female, Follow-Up Studies, Humans, Male, Prospective Studies.
Abstract
Objective: To compare the efficacy and safety of clozapine in drug induced psychosis in Parkinson’s disease (PD). Methods: A four week, randomised, double blind, parallel comparison of clozapine and placebo, followed by a 12 week clozapine open period, plus a one month period after drug discontinuation, in 60 patients with PD. The primary efficacy outcome was the “clinical global impression scale” (CGI); the positive subscore of the “positive and negative syndrome scale” (PANSS) was used as the secondary efficacy parameter and the “unified Parkinson’s disease rating scale” (UPDRS) and the “mini mental test examination” (MMSE) as safety outcomes. Results: The mean (SD) dosage of clozapine was 35.8 (12.5–50) mg at the end of the double blind period. The mean (SD) scores on the CGI improved by 1.8 (1.5) for the clozapine group compared with 0.6 (1.1) for the placebo group (p = 0.001). The mean (SD) positive subscore of PANSS improved by 5.6 (3.9) for the clozapine group (0.8 (2.8) for the placebo group; p < 0.0001). At the end of the open period, 25 patients had completely recovered from delusions and hallucinations, and 19 experienced a relapse within one month after the clozapine washout period. The UPDRS motor and MMSE mean scores did not change significantly in either group. Somnolence was more frequent with clozapine than with placebo. Conclusions: Clozapine at a mean dose lower than 50 mg/day improves drug induced psychosis in PD without significant worsening of motor function, and the effect wears off once the treatment stops.
Url:
- https://api.istex.fr/document/D8CE96F619CD308F9DD33D29A5CCFC4FF3A19292/fulltext/pdf
- http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1763590
DOI: 10.1136/jnnp.2003.029868
Affiliations:
- France
- Aquitaine, Auvergne (région administrative), Auvergne-Rhône-Alpes, Hauts-de-France, Midi-Pyrénées, Nord-Pas-de-Calais, Nouvelle-Aquitaine, Occitanie (région administrative), Rhône-Alpes, Île-de-France
- Clermont-Ferrand, Grenoble, Lille, Pessac, Rueil-Malmaison, Toulouse University Hospital
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 002417
- to stream Istex, to step Curation: 002415
- to stream Istex, to step Checkpoint: 000C31
- to stream Pmc, to step Corpus: 000496
- to stream Pmc, to step Curation: 000493
- to stream Pmc, to step Checkpoint: 000924
- to stream PubMed, to step Corpus: 001022
- to stream PubMed, to step Curation: 000F81
- to stream PubMed, to step Checkpoint: 000F81
- to stream Ncbi, to step Merge: 000434
- to stream Ncbi, to step Curation: 000434
- to stream Ncbi, to step Checkpoint: 000434
- to stream Main, to step Merge: 003347
- to stream PascalFrancis, to step Corpus: 000E23
- to stream PascalFrancis, to step Curation: 000611
- to stream PascalFrancis, to step Checkpoint: 000C62
- to stream Main, to step Merge: 003462
- to stream Main, to step Curation: 002F29
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Clozapine in drug induced psychosis in Parkinson’s disease: a randomised, placebo controlled study with open follow up</title><author><name sortKey="Pollak, P" sort="Pollak, P" uniqKey="Pollak P" first="P" last="Pollak">P. Pollak</name></author><author><name sortKey="Tison, F" sort="Tison, F" uniqKey="Tison F" first="F" last="Tison">F. Tison</name></author><author><name sortKey="Rascol, O" sort="Rascol, O" uniqKey="Rascol O" first="O" last="Rascol">O. Rascol</name></author><author><name sortKey="Destee, A" sort="Destee, A" uniqKey="Destee A" first="A" last="Destée">A. Destée</name></author><author><name sortKey="Pere, J J" sort="Pere, J J" uniqKey="Pere J" first="J J" last="Péré">J J Péré</name></author><author><name sortKey="Senard, J M" sort="Senard, J M" uniqKey="Senard J" first="J M" last="Senard">J M Senard</name></author><author><name sortKey="Durif, F" sort="Durif, F" uniqKey="Durif F" first="F" last="Durif">F. Durif</name></author><author><name sortKey="Bourdeix, I" sort="Bourdeix, I" uniqKey="Bourdeix I" first="I" last="Bourdeix">I. Bourdeix</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:D8CE96F619CD308F9DD33D29A5CCFC4FF3A19292</idno><date when="2004" year="2004">2004</date><idno type="doi">10.1136/jnnp.2003.029868</idno><idno type="url">https://api.istex.fr/document/D8CE96F619CD308F9DD33D29A5CCFC4FF3A19292/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">002417</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">002417</idno><idno type="wicri:Area/Istex/Curation">002415</idno><idno type="wicri:Area/Istex/Checkpoint">000C31</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">000C31</idno><idno type="wicri:doubleKey">0022-3050:2004:Pollak P:clozapine:in:drug</idno><idno type="wicri:source">PMC</idno><idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1763590</idno><idno type="RBID">PMC:1763590</idno><idno type="wicri:Area/Pmc/Corpus">000496</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">000496</idno><idno type="wicri:Area/Pmc/Curation">000493</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Curation">000493</idno><idno type="wicri:Area/Pmc/Checkpoint">000924</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Checkpoint">000924</idno><idno type="wicri:source">PubMed</idno><idno type="wicri:Area/PubMed/Corpus">001022</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001022</idno><idno type="wicri:Area/PubMed/Curation">000F81</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000F81</idno><idno type="wicri:Area/PubMed/Checkpoint">000F81</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000F81</idno><idno type="wicri:Area/Ncbi/Merge">000434</idno><idno type="wicri:Area/Ncbi/Curation">000434</idno><idno type="wicri:Area/Ncbi/Checkpoint">000434</idno><idno type="wicri:doubleKey">0022-3050:2004:Pollak P:clozapine:in:drug</idno><idno type="wicri:Area/Main/Merge">003347</idno><idno type="wicri:source">INIST</idno><idno type="RBID">Pascal:04-0274958</idno><idno type="wicri:Area/PascalFrancis/Corpus">000E23</idno><idno type="wicri:Area/PascalFrancis/Curation">000611</idno><idno type="wicri:Area/PascalFrancis/Checkpoint">000C62</idno><idno type="wicri:explorRef" wicri:stream="PascalFrancis" wicri:step="Checkpoint">000C62</idno><idno type="wicri:doubleKey">0022-3050:2004:Pollak P:clozapine:in:drug</idno><idno type="wicri:Area/Main/Merge">003462</idno><idno type="wicri:Area/Main/Curation">002F29</idno><idno type="wicri:Area/Main/Exploration">002F29</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Clozapine in drug induced psychosis in Parkinson’s disease: a randomised, placebo controlled study with open follow up</title><author><name sortKey="Pollak, P" sort="Pollak, P" uniqKey="Pollak P" first="P" last="Pollak">P. Pollak</name><affiliation wicri:level="3"><country xml:lang="fr">France</country><wicri:regionArea>Department of Neurology, University Hospital of Grenoble, 38043 Grenoble Cedex 9</wicri:regionArea><placeName><region type="region" nuts="2">Auvergne-Rhône-Alpes</region><region type="old region" nuts="2">Rhône-Alpes</region><settlement type="city">Grenoble</settlement></placeName></affiliation></author><author><name sortKey="Tison, F" sort="Tison, F" uniqKey="Tison F" first="F" last="Tison">F. Tison</name><affiliation wicri:level="3"><country xml:lang="fr">France</country><wicri:regionArea>Fédération de Neurologie, University Hospital of Bordeaux, 33604 Pessac</wicri:regionArea><placeName><region type="region" nuts="2">Nouvelle-Aquitaine</region><region type="old region" nuts="2">Aquitaine</region><settlement type="city">Pessac</settlement></placeName></affiliation></author><author><name sortKey="Rascol, O" sort="Rascol, O" uniqKey="Rascol O" first="O" last="Rascol">O. Rascol</name><affiliation wicri:level="3"><country xml:lang="fr">France</country><wicri:regionArea>Clinical Investigation Centre, Department of Clinical Pharmacology, INSERM U455, CHU Purpan, 31073 Toulouse University Hospital</wicri:regionArea><placeName><region type="region" nuts="2">Occitanie (région administrative)</region><region type="old region" nuts="2">Midi-Pyrénées</region><settlement type="city">Toulouse University Hospital</settlement></placeName></affiliation></author><author><name sortKey="Destee, A" sort="Destee, A" uniqKey="Destee A" first="A" last="Destée">A. Destée</name><affiliation wicri:level="3"><country xml:lang="fr">France</country><wicri:regionArea>Neurology and Movement Disorders Unit, Neurologie A, Hôpital Salengro, 59037 Lille</wicri:regionArea><placeName><region type="region" nuts="2">Hauts-de-France</region><region type="old region" nuts="2">Nord-Pas-de-Calais</region><settlement type="city">Lille</settlement></placeName></affiliation></author><author><name sortKey="Pere, J J" sort="Pere, J J" uniqKey="Pere J" first="J J" last="Péré">J J Péré</name><affiliation wicri:level="3"><country xml:lang="fr">France</country><wicri:regionArea>Novartis Pharma, 92506 Rueil-Malmaison</wicri:regionArea><placeName><region type="region" nuts="2">Île-de-France</region><settlement type="city">Rueil-Malmaison</settlement></placeName></affiliation></author><author><name sortKey="Senard, J M" sort="Senard, J M" uniqKey="Senard J" first="J M" last="Senard">J M Senard</name><affiliation wicri:level="3"><country xml:lang="fr">France</country><wicri:regionArea>Clinical Investigation Centre, Department of Clinical Pharmacology, INSERM U455, CHU Purpan, 31073 Toulouse University Hospital</wicri:regionArea><placeName><region type="region" nuts="2">Occitanie (région administrative)</region><region type="old region" nuts="2">Midi-Pyrénées</region><settlement type="city">Toulouse University Hospital</settlement></placeName></affiliation></author><author><name sortKey="Durif, F" sort="Durif, F" uniqKey="Durif F" first="F" last="Durif">F. Durif</name><affiliation wicri:level="3"><country xml:lang="fr">France</country><wicri:regionArea>Fédération de Neurologie, Hôpital Gabriel Montpied, 63033 Clermont-Ferrand Cedex I</wicri:regionArea><placeName><region type="region" nuts="2">Auvergne-Rhône-Alpes</region><region type="old region" nuts="2">Auvergne (région administrative)</region><settlement type="city">Clermont-Ferrand</settlement></placeName></affiliation></author><author><name sortKey="Bourdeix, I" sort="Bourdeix, I" uniqKey="Bourdeix I" first="I" last="Bourdeix">I. Bourdeix</name><affiliation wicri:level="1"><country xml:lang="fr">France</country><wicri:regionArea>Novartis Pharma, 92506 Rueil-Malmaison</wicri:regionArea><wicri:noRegion>92506 Rueil-Malmaison</wicri:noRegion><wicri:noRegion>92506 Rueil-Malmaison</wicri:noRegion></affiliation></author></analytic><monogr></monogr><series><title level="j">Journal of Neurology, Neurosurgery & Psychiatry</title><title level="j" type="abbrev">J Neurol Neurosurg Psychiatry</title><idno type="ISSN">0022-3050</idno><idno type="eISSN">1468-330X</idno><imprint><publisher>BMJ Publishing Group Ltd</publisher><date type="published" when="2004-05">2004-05</date><biblScope unit="volume">75</biblScope><biblScope unit="issue">5</biblScope><biblScope unit="page" from="689">689</biblScope></imprint><idno type="ISSN">0022-3050</idno></series><idno type="istex">D8CE96F619CD308F9DD33D29A5CCFC4FF3A19292</idno><idno type="DOI">10.1136/jnnp.2003.029868</idno><idno type="href">jnnp-75-689.pdf</idno><idno type="PMID">15090561</idno><idno type="local">0750689</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0022-3050</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Aged</term><term>CGI, clinical global impression scale</term><term>Clozapine</term><term>Clozapine (administration & dosage)</term><term>Clozapine (therapeutic use)</term><term>Dose-Response Relationship, Drug</term><term>Double-Blind Method</term><term>Feasibility Studies</term><term>Female</term><term>Follow up study</term><term>Follow-Up Studies</term><term>GABA Antagonists (administration & dosage)</term><term>GABA Antagonists (adverse effects)</term><term>Humans</term><term>Levodopa (adverse effects)</term><term>MMSE, mini mental test examination</term><term>Male</term><term>Nervous system diseases</term><term>PANSS, positive and negative syndrome scale</term><term>PD, Parkinson’s disease</term><term>Parkinson Disease (drug therapy)</term><term>Parkinson disease</term><term>Parkinson’s disease</term><term>Prospective Studies</term><term>Psychoses, Substance-Induced (diagnosis)</term><term>Psychoses, Substance-Induced (etiology)</term><term>Psychosis</term><term>UPDRS, unified Parkinson’s disease rating scale</term><term>clozapine</term><term>psychosis</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Clozapine</term><term>GABA Antagonists</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>GABA Antagonists</term><term>Levodopa</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Clozapine</term></keywords><keywords scheme="MESH" qualifier="diagnosis" xml:lang="en"><term>Psychoses, Substance-Induced</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Psychoses, Substance-Induced</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Aged</term><term>Dose-Response Relationship, Drug</term><term>Double-Blind Method</term><term>Feasibility Studies</term><term>Female</term><term>Follow-Up Studies</term><term>Humans</term><term>Male</term><term>Prospective Studies</term></keywords><keywords scheme="Pascal" xml:lang="fr"><term>Clozapine</term><term>Etude longitudinale</term><term>Parkinson maladie</term><term>Psychose</term><term>Système nerveux pathologie</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Objective: To compare the efficacy and safety of clozapine in drug induced psychosis in Parkinson’s disease (PD). Methods: A four week, randomised, double blind, parallel comparison of clozapine and placebo, followed by a 12 week clozapine open period, plus a one month period after drug discontinuation, in 60 patients with PD. The primary efficacy outcome was the “clinical global impression scale” (CGI); the positive subscore of the “positive and negative syndrome scale” (PANSS) was used as the secondary efficacy parameter and the “unified Parkinson’s disease rating scale” (UPDRS) and the “mini mental test examination” (MMSE) as safety outcomes. Results: The mean (SD) dosage of clozapine was 35.8 (12.5–50) mg at the end of the double blind period. The mean (SD) scores on the CGI improved by 1.8 (1.5) for the clozapine group compared with 0.6 (1.1) for the placebo group (p = 0.001). The mean (SD) positive subscore of PANSS improved by 5.6 (3.9) for the clozapine group (0.8 (2.8) for the placebo group; p < 0.0001). At the end of the open period, 25 patients had completely recovered from delusions and hallucinations, and 19 experienced a relapse within one month after the clozapine washout period. The UPDRS motor and MMSE mean scores did not change significantly in either group. Somnolence was more frequent with clozapine than with placebo. Conclusions: Clozapine at a mean dose lower than 50 mg/day improves drug induced psychosis in PD without significant worsening of motor function, and the effect wears off once the treatment stops.</div></front></TEI><affiliations><list><country><li>France</li></country><region><li>Aquitaine</li><li>Auvergne (région administrative)</li><li>Auvergne-Rhône-Alpes</li><li>Hauts-de-France</li><li>Midi-Pyrénées</li><li>Nord-Pas-de-Calais</li><li>Nouvelle-Aquitaine</li><li>Occitanie (région administrative)</li><li>Rhône-Alpes</li><li>Île-de-France</li></region><settlement><li>Clermont-Ferrand</li><li>Grenoble</li><li>Lille</li><li>Pessac</li><li>Rueil-Malmaison</li><li>Toulouse University Hospital</li></settlement></list><tree><country name="France"><region name="Auvergne-Rhône-Alpes"><name sortKey="Pollak, P" sort="Pollak, P" uniqKey="Pollak P" first="P" last="Pollak">P. Pollak</name></region><name sortKey="Bourdeix, I" sort="Bourdeix, I" uniqKey="Bourdeix I" first="I" last="Bourdeix">I. Bourdeix</name><name sortKey="Destee, A" sort="Destee, A" uniqKey="Destee A" first="A" last="Destée">A. Destée</name><name sortKey="Durif, F" sort="Durif, F" uniqKey="Durif F" first="F" last="Durif">F. Durif</name><name sortKey="Pere, J J" sort="Pere, J J" uniqKey="Pere J" first="J J" last="Péré">J J Péré</name><name sortKey="Rascol, O" sort="Rascol, O" uniqKey="Rascol O" first="O" last="Rascol">O. Rascol</name><name sortKey="Senard, J M" sort="Senard, J M" uniqKey="Senard J" first="J M" last="Senard">J M Senard</name><name sortKey="Tison, F" sort="Tison, F" uniqKey="Tison F" first="F" last="Tison">F. Tison</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonFranceV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002F29 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 002F29 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonFranceV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:D8CE96F619CD308F9DD33D29A5CCFC4FF3A19292
|texte= Clozapine in drug induced psychosis in Parkinson’s disease: a randomised, placebo controlled study with open follow up
}}
| This area was generated with Dilib version V0.6.29. |  |